Oncology Drug Reference Sheet: Zanubrutinib
Kristine B. LeFebvre DNP, RN, NPD-BC, AOCN®
Voice
Description
Zanubrutinib (Brukinsa™) received U.S. Food and Drug Administration accelerated approval on November 14, 2019, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education